MA40523A - 2-(morpholin-4-yl)-1,7-naphthyridines - Google Patents

2-(morpholin-4-yl)-1,7-naphthyridines

Info

Publication number
MA40523A
MA40523A MA040523A MA40523A MA40523A MA 40523 A MA40523 A MA 40523A MA 040523 A MA040523 A MA 040523A MA 40523 A MA40523 A MA 40523A MA 40523 A MA40523 A MA 40523A
Authority
MA
Morocco
Prior art keywords
compounds
morpholin
preparation
naphthyridines
disease
Prior art date
Application number
MA040523A
Other languages
English (en)
Other versions
MA40523B1 (fr
Inventor
Benjamin Bader
Wilhelm Bone
Hans Briem
Uwe Eberspächer
Knut Eis
Joanna Grudzinska-Goebel
Marcus Koppitz
Julien Lefranc
Philip Lienau
Ulrich Lücking
Dieter Moosmayer
Hans Schick
Gerhard Siemeister
Nussbaum Franz Von
Antje Margret Wengner
Lars Wortmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA40523A publication Critical patent/MA40523A/fr
Publication of MA40523B1 publication Critical patent/MA40523B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention porte sur des composés 2-(morpholin-4-yl)-l,7-naphtyridine substitués représentés par la formule générale (i) ou (ib), sur des procédés de préparation desdits composés, sur des composés intermédiaires utiles pour la préparation desdits composés, sur des combinaisons et des compositions pharmaceutiques comprenant lesdits composés et sur l'utilisation desdits composés pour la fabrication d'une composition pharmaceutique utile pour le traitement ou la prophylaxie d'une maladie, en particulier d'une maladie hyperproliférative en tant qu'agent unique ou en combinaison avec d'autres principes actifs.
MA40523A 2014-08-04 2015-08-03 2-(morpholin-4-yl)-1,7-naphthyridines MA40523B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14179692 2014-08-04
EP15159342 2015-03-17
EP15744596.6A EP3177619B1 (fr) 2014-08-04 2015-08-03 2-(morpholin-4-yl)-1,7-naphthyridines
PCT/EP2015/067804 WO2016020320A1 (fr) 2014-08-04 2015-08-03 2- (morpholin -4-yl)-l,7-naphtyridines

Publications (2)

Publication Number Publication Date
MA40523A true MA40523A (fr) 2017-06-14
MA40523B1 MA40523B1 (fr) 2018-09-28

Family

ID=53762196

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40523A MA40523B1 (fr) 2014-08-04 2015-08-03 2-(morpholin-4-yl)-1,7-naphthyridines

Country Status (42)

Country Link
US (4) US9993484B2 (fr)
EP (2) EP3177619B1 (fr)
JP (2) JP6266839B2 (fr)
KR (2) KR102317169B1 (fr)
CN (3) CN106795156B (fr)
AP (1) AP2017009702A0 (fr)
AU (2) AU2015299173B2 (fr)
BR (1) BR112017002221B1 (fr)
CA (1) CA2956992C (fr)
CL (1) CL2017000287A1 (fr)
CO (1) CO2017001035A2 (fr)
CR (1) CR20170034A (fr)
CU (1) CU24419B1 (fr)
CY (2) CY1120673T1 (fr)
DK (2) DK3395818T3 (fr)
DO (1) DOP2017000038A (fr)
EA (2) EA031678B1 (fr)
EC (1) ECSP17007538A (fr)
ES (2) ES2679625T3 (fr)
HR (2) HRP20211770T1 (fr)
HU (2) HUE056676T2 (fr)
IL (2) IL250220B (fr)
JO (1) JO3447B1 (fr)
LT (2) LT3177619T (fr)
MA (1) MA40523B1 (fr)
MX (2) MX394442B (fr)
MY (1) MY192883A (fr)
NI (1) NI201700011A (fr)
PE (1) PE20170666A1 (fr)
PH (2) PH12017500204B1 (fr)
PL (2) PL3395818T3 (fr)
PT (1) PT3177619T (fr)
RS (2) RS57445B1 (fr)
SA (1) SA517380830B1 (fr)
SG (1) SG11201700750UA (fr)
SI (2) SI3177619T1 (fr)
TN (1) TN2017000027A1 (fr)
TW (2) TWI656121B (fr)
UA (2) UA121036C2 (fr)
UY (1) UY36254A (fr)
WO (1) WO2016020320A1 (fr)
ZA (1) ZA202101003B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3177612T (lt) 2014-08-04 2022-06-10 Nuevolution A/S Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
WO2017121684A1 (fr) * 2016-01-14 2017-07-20 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines substituées en 5
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018153972A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr et d'anti-androgènes
EP3585436A1 (fr) 2017-02-24 2020-01-01 Bayer AS Polythérapie comprenant un agent radiopharmaceutique et un inhibiteur de réparation d'adn
WO2018153971A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr
WO2018153970A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Formes solides de 2-[(3r)-3-méthylmorpholin-4-yl]-4-(1-méthyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphtyridine
JOP20190197A1 (ar) * 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
TW201840319A (zh) 2017-02-24 2018-11-16 德商拜耳廠股份有限公司 Atr激酶抑制劑與鐳-223鹽之組合
CA3054247A1 (fr) 2017-02-24 2018-08-30 Antje Margret Wengner Combinaison d'inhibiteurs de la kinase atr et d'inhibiteurs de parp
WO2018206547A1 (fr) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de bub1 et d'atr
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
DK3651768T3 (da) * 2017-07-13 2024-03-18 Univ Texas Heterocykliske inhibitorer af atr-kinase
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (fr) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft Dérivés 6-((3-trifluorométhyl)phényl)-4,5-dihydropyridazin-3(2h)-one en tant qu'inhibiteurs de pde3a et pde3b pour le traitement du cancer
US10800774B2 (en) 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
WO2019057852A1 (fr) 2017-09-22 2019-03-28 Bayer Aktiengesellschaft Utilisation de kap1 en tant que biomarqueur pour la détection ou la surveillance de l'inhibition d'atr chez un sujet
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
US11712440B2 (en) * 2017-12-08 2023-08-01 Bayer Aktiengesellschaft Predictive markers for ATR kinase inhibitors
FI3753937T3 (fi) * 2018-02-07 2024-01-31 Wuxi Biocity Biopharmaceutics Co Ltd Atr-inhibiittori ja sen sovellus
CN112218631B (zh) * 2018-03-16 2023-12-22 德州大学系统董事会 Atr激酶的杂环抑制剂
AU2019324521B9 (en) * 2018-08-24 2024-11-14 Bayer Aktiengesellschaft Method for preparing 2-((3R)-3-methylmorpholin-4-yl)-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine
US20210369724A1 (en) * 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
AU2020215088A1 (en) 2019-02-01 2021-07-22 Bayer Aktiengesellschaft 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases
MA54928A (fr) * 2019-02-11 2021-12-22 Bayer Ag Inhibiteur de kinase atr bay1895344 destiné à être utilisé dans le traitement d'une maladie hyper-proliférative
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
US12559488B2 (en) 2019-11-21 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. Substituted morpholines as ATR kinase inhibitors
CN115103677A (zh) * 2019-12-11 2022-09-23 修复治疗公司 Atr抑制剂与parp抑制剂的组合的用途
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
CN116134022B (zh) * 2020-07-03 2025-03-18 上海德琪医药科技有限公司 Atr抑制剂和其用途
IL299804A (en) * 2020-07-13 2023-03-01 Beijing Tide Pharmaceutical Co Ltd Pyrazolopyrimidine compounds for use as ATR kinase inhibitors
CN112110934B (zh) * 2020-09-23 2021-12-07 上海应用技术大学 一种基于azd9291的生物标记物及其制备方法与应用
US20240043419A1 (en) * 2020-09-27 2024-02-08 Medshine Discovery Inc. Class of 1,7-naphthyridine compounds and application thereof
KR20230088709A (ko) * 2020-10-16 2023-06-20 상하이 드 노보 파마테크 컴퍼니 리미티드 트리헤테로사이클릭 유도체, 이의 약학적 조성물 및 용도
US20240059695A1 (en) * 2020-12-25 2024-02-22 Impact Therapeutics (Shanghai), Inc SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF
JP2024517906A (ja) * 2021-05-12 2024-04-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド スルホンイミドイル含有ａｔｒ阻害剤化合物
TW202313604A (zh) 2021-05-21 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 吡唑並雜芳基類衍生物的可藥用鹽及其結晶形式
IL310412A (en) 2021-07-27 2024-03-01 Littdd Medicines Ltd 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CA3227336A1 (fr) * 2021-08-11 2023-02-16 Yuli Xie Derive de naphtyridine utile comme inhibiteur de l'atr et son procede de preparation
CN116283960A (zh) 2021-12-21 2023-06-23 上海安诺达生物科技有限公司 取代的稠杂环化合物及其制备方法与应用
CN116731011A (zh) * 2022-03-01 2023-09-12 武汉众诚康健生物医药科技有限公司 一种萘啶衍生物及其应用
CN116925070B (zh) * 2022-04-24 2026-03-17 扬子江药业集团有限公司 取代的氮杂稠环化合物及其医药用途
AU2023290506A1 (en) 2022-06-15 2025-01-23 Astrazeneca Ab Combination therapy for treating cancer
WO2024188937A1 (fr) 2023-03-13 2024-09-19 Bayer Aktiengesellschaft Associations d'inhibiteurs de kinase atr et d'inhibiteurs de parp pour traiter des affections hyper-prolifératives, par exemple un cancer
WO2025015238A2 (fr) * 2023-07-12 2025-01-16 Kansas State University Research Foundation N-oxydes de n-méthylmorpholine substitués chiraux et leurs procédés de fabrication et d'utilisation
WO2025181153A1 (fr) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Utilisation d'inhibiteurs d'atr en combinaison avec des inhibiteurs de pi3k alpha
WO2025229051A1 (fr) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Utilisation d'inhibiteurs d'atr en combinaison avec un agent anti-androgène
WO2025233224A1 (fr) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Utilisation d'inhibiteurs d'atr en combinaison avec une thérapie anti-pd(l)1

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
US4008068A (en) * 1976-03-08 1977-02-15 Velsicol Chemical Corporation 1-Thiadiazolyl-5-morpholinoimidazolidinones
AU4007900A (en) 1999-03-11 2000-10-16 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2007000445A1 (fr) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
EP1954699B1 (fr) * 2005-11-22 2012-09-19 Kudos Pharmaceuticals Ltd DÉRIVÉS DE PYRIDO-, PYRAZO- ET PYRIMIDOPYRIMIDINE EN TANT QU'INHIBITEURS DE mTOR
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (fr) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft Dérivés (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide en tant qu'inhibiteurs de la kinase aurora pour le traitement de cancer
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
ES2301380B1 (es) * 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
AU2007287430B2 (en) * 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
BRPI0918496A2 (pt) * 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
WO2010037765A2 (fr) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
MX2011004953A (es) 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
US20100144345A1 (en) 2008-12-09 2010-06-10 Microsoft Corporation Using called party mobile presence and movement in communication application
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
TW201028410A (en) * 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
EP2569286B1 (fr) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Composés utilisables en tant qu'inhibiteurs de la kinase atr
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603478A (en) 2010-05-12 2014-09-26 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase
EP2569313A1 (fr) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
WO2011143419A1 (fr) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines utiles en tant qu'inhibiteurs de la kinase atr
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
EP2585468A1 (fr) * 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Dérivés de pyrrolo-pyrazine utiles en tant qu'inhibiteurs de l'atr kinase
AU2011272862A1 (en) * 2010-06-30 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
AU2012240030A1 (en) 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
WO2012178123A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2723747A1 (fr) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Composés utiles comme inhibiteurs de la kinase atr
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CA2850564A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de kinase atr
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
RU2018108589A (ru) 2011-09-30 2019-02-25 Вертекс Фармасьютикалз Инкорпорейтед Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
WO2013049720A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase atr
WO2013071090A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
EP2776420A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés de pyrazine utiles comme inhibiteurs de kinase atr
EP2776429A1 (fr) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
EP2909202A1 (fr) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
WO2014089379A1 (fr) 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs d'atr kinase
CN104903320B (zh) 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
WO2017121684A1 (fr) * 2016-01-14 2017-07-20 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines substituées en 5
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
CA3054247A1 (fr) 2017-02-24 2018-08-30 Antje Margret Wengner Combinaison d'inhibiteurs de la kinase atr et d'inhibiteurs de parp
WO2018153970A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Formes solides de 2-[(3r)-3-méthylmorpholin-4-yl]-4-(1-méthyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphtyridine
TW201840319A (zh) 2017-02-24 2018-11-16 德商拜耳廠股份有限公司 Atr激酶抑制劑與鐳-223鹽之組合
WO2018153972A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr et d'anti-androgènes
WO2018153971A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr
EP3585436A1 (fr) 2017-02-24 2020-01-01 Bayer AS Polythérapie comprenant un agent radiopharmaceutique et un inhibiteur de réparation d'adn
WO2018206547A1 (fr) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de bub1 et d'atr
EP3646075B1 (fr) 2017-06-28 2025-07-30 Corning Research & Development Corporation Multiports ayant des ports de connexion avec des éléments de fixation qui actionnent des flexions et leurs procédés de fabrication
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
US11712440B2 (en) 2017-12-08 2023-08-01 Bayer Aktiengesellschaft Predictive markers for ATR kinase inhibitors
AU2019324521B9 (en) 2018-08-24 2024-11-14 Bayer Aktiengesellschaft Method for preparing 2-((3R)-3-methylmorpholin-4-yl)-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine
MX2021003944A (es) 2018-10-05 2021-07-16 Isp Investments Llc Composicion del recubrimiento de pelicula liso alto en solidos que comprende eter de celulosa soluble en agua, proceso para la preparacion de este y metodo de uso del mismo.
US20210369724A1 (en) 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
MA54928A (fr) 2019-02-11 2021-12-22 Bayer Ag Inhibiteur de kinase atr bay1895344 destiné à être utilisé dans le traitement d'une maladie hyper-proliférative

Also Published As

Publication number Publication date
BR112017002221B1 (pt) 2023-02-28
CO2017001035A2 (es) 2017-05-31
US20160287604A1 (en) 2016-10-06
JP2017523987A (ja) 2017-08-24
IL250220A0 (en) 2017-03-30
TN2017000027A1 (en) 2018-07-04
CY1120673T1 (el) 2019-12-11
LT3395818T (lt) 2021-11-25
ZA202101003B (en) 2022-09-28
AP2017009702A0 (en) 2017-01-31
HUE038533T2 (hu) 2018-10-29
AU2015299173B2 (en) 2019-03-14
CR20170034A (es) 2017-04-06
IL268969B (en) 2020-03-31
UY36254A (es) 2016-02-29
AU2019204125A1 (en) 2019-07-04
KR102317169B1 (ko) 2021-10-27
UA121036C2 (uk) 2020-03-25
CU24419B1 (es) 2019-05-03
US9549932B2 (en) 2017-01-24
EP3395818A1 (fr) 2018-10-31
MX394442B (es) 2025-03-24
KR20200130755A (ko) 2020-11-19
US20170216304A1 (en) 2017-08-03
MX2020010333A (es) 2022-08-03
AU2019204125B2 (en) 2020-06-25
KR102180006B1 (ko) 2020-11-18
HUE056676T2 (hu) 2022-02-28
TWI700283B (zh) 2020-08-01
EP3177619A1 (fr) 2017-06-14
CL2017000287A1 (es) 2017-11-10
CA2956992C (fr) 2024-10-29
EA031678B1 (ru) 2019-02-28
CN110256427A (zh) 2019-09-20
NZ728416A (en) 2021-11-26
KR20170040300A (ko) 2017-04-12
UA123928C2 (uk) 2021-06-23
WO2016020320A8 (fr) 2017-04-06
EA201790306A1 (ru) 2017-08-31
IL268969A (en) 2019-10-31
TWI656121B (zh) 2019-04-11
PE20170666A1 (es) 2017-06-15
PL3177619T3 (pl) 2018-09-28
DK3395818T3 (en) 2021-12-13
JO3447B1 (ar) 2020-07-05
SG11201700750UA (en) 2017-02-27
CA2956992A1 (fr) 2016-02-11
MX2017001637A (es) 2017-04-27
CN110204544B (zh) 2022-04-12
US9993484B2 (en) 2018-06-12
CN106795156B (zh) 2019-07-30
JP6266839B2 (ja) 2018-01-24
IL250220B (en) 2019-09-26
MA40523B1 (fr) 2018-09-28
CY1124855T1 (el) 2022-11-25
WO2016020320A1 (fr) 2016-02-11
EP3395818B1 (fr) 2021-09-22
ECSP17007538A (es) 2017-03-31
PH12021550792A1 (en) 2021-12-13
NZ765780A (en) 2023-11-24
ES2900599T3 (es) 2022-03-17
ES2679625T3 (es) 2018-08-29
US11529356B2 (en) 2022-12-20
CN110256427B (zh) 2022-02-22
DK3177619T3 (en) 2018-08-06
US20200383991A1 (en) 2020-12-10
BR112017002221A2 (pt) 2018-05-22
HRP20211770T1 (hr) 2022-02-18
MY192883A (en) 2022-09-13
HRP20181143T1 (hr) 2018-09-21
RS62609B1 (sr) 2021-12-31
US10772893B2 (en) 2020-09-15
CN110204544A (zh) 2019-09-06
PL3395818T3 (pl) 2022-01-31
TW201922746A (zh) 2019-06-16
DOP2017000038A (es) 2018-04-15
NI201700011A (es) 2017-04-20
SI3395818T1 (sl) 2022-01-31
CU20170009A7 (es) 2017-07-04
TW201613920A (en) 2016-04-16
PH12017500204B1 (en) 2022-07-29
EA201891861A1 (ru) 2019-01-31
JP6507216B2 (ja) 2019-04-24
PH12017500204A1 (en) 2017-07-10
LT3177619T (lt) 2018-08-10
RS57445B1 (sr) 2018-09-28
JP2018062517A (ja) 2018-04-19
EA035039B1 (ru) 2020-04-21
CN106795156A (zh) 2017-05-31
SI3177619T1 (en) 2018-08-31
PT3177619T (pt) 2018-07-24
SA517380830B1 (ar) 2021-01-18
MX376270B (es) 2025-03-07
US20180256591A1 (en) 2018-09-13
EP3177619B1 (fr) 2018-04-25

Similar Documents

Publication Publication Date Title
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA45020A (fr) Dérivés sulfonamides aromatiques
MA59379B1 (fr) Aminothiazoles substitués en tant qu'inhibiteurs de dgkzeta pour l'activation immunitaire
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
EA202090448A1 (ru) Дигидрооксадиазиноны
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA38358A1 (fr) Formulations de composés organiques
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA43553B1 (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA37849A1 (fr) Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux
MA38642A1 (fr) Compositions pharmaceutiques de composes triazolopyridines substitues pour une utilsation en tant qu'agents anticancereux
MA38774A1 (fr) Pyrazolo-pyridinamines substituees inhibiteurs de mknk1 kinase pour une utilisation dans les troubles hyperproliferatifs et/ou relatifs a l'angiogenese.
MA39041B1 (fr) Thiénopyrimidines en tant qu'inhibiteurs de mknk1 et de mknk2